Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Annual Report 2016

Annual Report 2016

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

ASCO 2017 - A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

ASCO 2017 - A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

First Quarter 2017 Business Update

First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents